eIF2A in translational control
eIF2A in translational control
批准号:
10539309
负责人:
Anton A. Komar
金额:
$29.2万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-01-15 至 2024-12-31
关键词:
3T3-L1 CellsAdipocytesAffectAge MonthsAntigen PresentationApoptosisBindingBiochemicalCell Cycle ProgressionCell LineCell modelCellsCharacteristicsCodon NucleotidesComplexCryoelectron MicroscopyDevelopmentDiabetes MellitusDiseaseDrug TargetingEIF-2alphaEscherichia coliEtiologyEukaryotaEukaryotic Initiation FactorsEventFatty LiverGene ExpressionGene Expression RegulationGenesGenetic TranscriptionGoalsGuanosine TriphosphateHigh Fat DietHomeostasisHomologous GeneIn VitroKnock-outKnockout MiceLinkLipidsLymphomaMajor Histocompatibility ComplexMalignant NeoplasmsMammalsMediatingMessenger RNAMetabolicMetabolic DiseasesMetabolic syndromeMinorModelingMolecularMouse StrainsMusObesityOutcomePathway interactionsPeptide Initiation FactorsPhenotypePhosphorylationPhosphotransferasesPhysiologicalPlayPredispositionProcessProductionPropertyProtein BiosynthesisProteinsReactionRecombinant ProteinsRecombinantsRegulationReportingResistanceRibosomesRoleSerumStimulusStressStructureSystemTP53 geneTestingTimeTissuesTransfer RNATranslationsValidationViral Proteinsbiological adaptation to stresscell growthglucose tolerancehuman diseasein vivoinnovationinterestknockout animalmouse modelpolypeptidepreferencereconstitutionrecruitresponseribosome profilingtranscriptometranscriptome sequencingtranslation assaytranslatometumortumor initiationtumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Initiation of protein synthesis in eukaryotes is a complex process requiring more than 12 different initiation
factors, comprising over 30 polypeptide chains. The functions of many of these factors have been established
in great detail; however, the precise role of some of them and their mechanism of action still remain not well
understood. eIF2A is a single chain 65 kDa protein that was initially believed to serve as the functional
homologue of prokaryotic IF2, since eIF2A and IF2 catalyze biochemically similar reactions, i.e. they stimulate
initiator methionyl-tRNA (Met-tRNAMeti) binding to the small ribosomal subunit. However, subsequent
identification of a heterotrimeric 126 kDa factor, eIF2() showed that this factor and not eIF2A is primarily
responsible for the binding of Met-tRNAMeti to 40S ribosomal subunits in eukaryotes. In mammals, four stress-
activated kinases reduce the level of active eIF2 by phosphorylating the eIF2subunit and, consequently,
reducing the global level of translation. However, translation of many cellular and viral proteins appeared to be
resistant to eIF2α phosphorylation despite requiring Met-tRNAMeti. It was found that a subset of factors,
including eIF2A, can promote efficient recruitment of Met-tRNAMeti to 40S/mRNA complexes under conditions
of inhibition of eIF2 activity, or its absence. Recently, eIF2A was also reported to be involved in non-AUG
dependent initiation in higher eukaryotes and the control of antigen presentation by major histocompatibility
complex (MHC) class I molecules, the integrated stress response and tumor initiation and progression. All of
these events were affected by eIF2A silencing in cellular models. Yet, the precise role of eIF2A in vivo, as well
as the precise mechanism of its action still remain largely enigmatic. There is a fundamental gap in our
understanding of how eIF2A functions in mammalian systems in vivo and ex vivo. To fill in this gap above and
to continue the physical and functional characterization of a eukaryotic/mammalian eIF2A, we have created a
viable homozygous eIF2A-total knockout mouse strain and obtained recombinant eIF2A expressed in E. coli
cells. The ultimate goal of this proposal is to understand the function of eIF2A in vivo and in vitro. This goal will
be achieved by a combination of in vitro, ex vivo and in vivo (mouse model) approaches. The outcome of this
proposal will be important for understanding the basic mechanisms of the translational control of gene
expression in higher eukaryotes, especially as part of the stress response.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3390/molecules28052383
发表时间:
2023-03-05
期刊:
Molecules (Basel, Switzerland)
影响因子:
--
作者:
[Komar AA]
通讯作者:
Komar AA
DOI:
10.1080/15384101.2022.2062186
发表时间:
2022-08
期刊:
Cell cycle (Georgetown, Tex.)
影响因子:
--
作者:
[Komar AA]
通讯作者:
Komar AA
DOI:
10.1128/jvi.01678-21
发表时间:
2022-01-26
期刊:
Journal of virology
影响因子:
5.4
作者:
[Basu A, Penumutchu S, Nguyen K, Mbonye U, Tolbert BS, Karn J, Komar AA, Mazumder B]
通讯作者:
Mazumder B
DOI:
10.1134/s0006297921080083
发表时间:
2021-08
期刊:
Biochemistry. Biokhimiia
影响因子:
--
作者:
[Komar AA]
通讯作者:
Komar AA
Cell-free Translation: Preparation and Validation of Translation-competent Extracts from Saccharomyces cerevisiae.
无细胞翻译:酿酒酵母具有翻译能力的提取物的制备和验证。
DOI:
10.21769/bioprotoc.4093
发表时间:
2021
期刊:
Bio-protocol
影响因子:
0.8
作者:
[Trainor,BrandonM, Komar,AntonA, Pestov,DimitriG, Shcherbik,Natalia]
通讯作者:
Shcherbik,Natalia
eIF2A in translational control
-
批准号:10348143
-
项目类别:
-
资助金额:$29.2万
-
财政年份:2020
-
负责人:Anton A. Komar
-
依托单位:
Safer and more effective FIX therapeutics: impact of codon optimization
-
批准号:10372111
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2020
-
负责人:Anton A. Komar
-
依托单位:
Safer and more effective FIX therapeutics: impact of codon optimization
-
批准号:10600842
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2020
-
负责人:Anton A. Komar
-
依托单位:
eIF2A in translational control
-
批准号:9883230
-
项目类别:
-
资助金额:$30.16万
-
财政年份:2020
-
负责人:Anton A. Komar
-
依托单位:
Understanding the impact of disease causing mutations in FIX
-
批准号:8752096
-
项目类别:
-
资助金额:$43.65万
-
财政年份:2014
-
负责人:Anton A. Komar
-
依托单位:
国内基金
海外基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制
-
批准号:81970721
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:陶凌
-
依托单位: